June 16, 2021
Austin-Based Angstrom Bio, Inc., Announces $3 Million Investment from GreyBird Ventures to Launch COVID-19 Variant Identification Diagnostic
Angstrom Bio, Inc., a company that is leveraging the power of third- generation sequencing to develop new classes of information-rich, sequencing-based molecular diagnostics, today announced a $3 million investment led by GreyBird Ventures. In conjunction with the financing, the company also welcomed GreyBird Co-Founders Scott Gazelle and Tom Miller to its board of directors.
Read More...
‍

October 13, 2020
Angstrom Bio Launches AMPD™, a Platform for High-Accuracy, High-Frequency COVID-19 and Respiratory Pathogen Testing
Angstrom Bio, Inc. today announces the launch of AMPD™, its nanopore sequencing- and machine learning-powered platform for high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing. AMPD leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza, and to enable schools and places of work to reopen safely and confidently. 
Read More...
‍